Skip to main content
Clinical Trials/NCT01786057
NCT01786057
Unknown
Phase 2

The Effect of Extracorporeal Shock Wave Therapy (ESWT)of Gastrosoleus Trigger Points in Patients With Plantar Fasciitis

Isfahan University of Medical Sciences1 site in 1 country48 target enrollmentNovember 2012

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Plantar Fasciitis
Sponsor
Isfahan University of Medical Sciences
Enrollment
48
Locations
1
Primary Endpoint
Change from baseline in pain severity after 3 weeks
Last Updated
13 years ago

Overview

Brief Summary

Plantar fasciitis is one of the most common causes of heel pain. This study will be performed in the purpose of determination the effects of extracorporeal shock wave therapy of gastrosoleus trigger points in patients with plantar fasciitis

Detailed Description

Plantar fasciitis is the most common cause of inferior heel pain, A great variety of therapies have been reported for the treatment of plantar fasciitis including extracorporeal shock wave therapy. Gastrosoleus muscle dysfunction is one of the most common contributing factors to this disease .Despite the long history and the fact that this is a common diagnosis made in clinical practice, the exact cause and best treatment for this condition still are being explored. Although there is lack of high-quality studies demonstrating the efficacy of extracorporeal shock wave therapy of gastrosoleus trigger points in patients with plantar fasciitis , this study will be performed to examine the effect of extracorporeal shock wave therapy of gastrosoleus trigger points in patients with plantar fasciitis

Registry
clinicaltrials.gov
Start Date
November 2012
End Date
October 2013
Last Updated
13 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Farnaz Dehgan Hosseinabadi

Dr.

Isfahan University of Medical Sciences

Eligibility Criteria

Inclusion Criteria

  • clinical diagnosis of plantar fasciitis
  • having at least one Gastrosoleus trigger point concomitantly.
  • having no response to conservative treatments for at least 3 months
  • willingness to participate

Exclusion Criteria

  • Dysfunction of the knee or ankle
  • Neurologic abnormalities
  • Bleeding tendency (hereditary or acquired)
  • Nerve entrapment syndrome
  • A previous operation on the heel
  • Evidences of Infection in lower limbs
  • A medical History of tumor
  • previous local corticosteroid injection within 12 weeks

Outcomes

Primary Outcomes

Change from baseline in pain severity after 3 weeks

Time Frame: Up to 4 weeks

The pain score (100 mm Visual Analogue Score ) is evaluated before the first session and 4 weeks after the last session.

Secondary Outcomes

  • Change from baseline in pain degree after 2 months.(Up to 2 months)

Study Sites (1)

Loading locations...

Similar Trials